Posted by Michael Wonder on 18 Apr 2026
Bracco receives Health Canada approval for Vueway injection (gadopiclenol), advancing lower dose MRI contrast imaging
17 April 2026 - Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose.
Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved Vueway injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent for use in contrast enhanced magnetic resonance imaging.
